Top

Published in:

Open Access 01-12-2023 | Meningioma | Review

Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis

Authors: Gregory Cello, Ruchit V. Patel, James Tanner McMahon, Sandro Santagata, Wenya Linda Bi

Published in: Acta Neuropathologica Communications | Issue 1/2023

Abstract

Trimethylation of lysine 27 on histone 3 (H3K27me3) loss has been implicated in worse prognoses for patients with meningiomas. However, there have been challenges in measuring H3K27me3 loss, quantifying its impact, and interpreting its clinical utility. We conducted a systematic review across Pubmed, Embase, and Web of Science to identify studies examining H3K27me3 loss in meningioma. Clinical, histopathological, and immunohistochemistry (IHC) characteristics were aggregated. A meta-analysis was performed using a random-effects model to assess prevalence of H3K27me3 loss and meningioma recurrence risk. Study bias was characterized using the NIH Quality Assessment Tool and funnel plots. Nine publications met inclusion criteria with a total of 2376 meningioma cases. The prevalence of H3K27me3 loss was 16% (95% CI 0.09–0.27), with higher grade tumors associated with a significantly greater proportion of loss. H3K27me3 loss was more common in patients who were male, had recurrent meningiomas, or required adjuvant radiation therapy. Patients were 1.70 times more likely to have tumor recurrence with H3K27me3 loss (95% CI 1.35–2.15). The prevalence of H3K27me3 loss in WHO grade 2 and 3 meningiomas was found to be significantly greater in tissue samples less than five years old versus tissue of all ages and when a broader definition of IHC staining loss was applied. This analysis demonstrates that H3K27me3 loss significantly associates with more aggressive meningiomas. While differences in IHC and tumor tissue age have led to heterogeneity in studying H3K27me3 loss, a robust prognostic signal is present. Our findings suggest an opportunity to improve study design and standardize tissue processing to optimize clinical viability of this epigenetic marker.

Available only for authorised users

Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, Folkerth RD, Ligon KL, Ligon AH, Alexander BM, Dunn IF, Beroukhim R, Santagata S (2016) Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol 18:649–655. https://doi.org/10.1093/neuonc/nov316CrossRefPubMedPubMedCentral

van Alkemade H, de Leau M, Dieleman EMT, Kardaun JWPF, van Os R, Vandertop WP, van Furth WR, Stalpers LJA (2012) Impaired survival and long-term neurological problems in benign meningioma. Neuro Oncol 14:658–666. https://doi.org/10.1093/neuonc/nos013CrossRefPubMedPubMedCentral

Al-Mefty O, Kadri PAS, Pravdenkova S, Sawyer JR, Stangeby C, Husain M (2004) Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 101:210–218. https://doi.org/10.3171/jns.2004.101.2.0210CrossRefPubMed

Ammendola S, Rizzo PC, Longhi M, Zivelonghi E, Pedron S, Pinna G, Sala F, Nicolato A, Scarpa A, Barresi V (2022) The immunohistochemical loss of H3K27me3 in intracranial meningiomas predicts shorter progression-free survival after stereotactic radiosurgery. Cancers (Basel) 14:1. https://doi.org/10.3390/cancers14071718CrossRef

Ayerbe J, Lobato RD, de la Cruz J, Alday R, Rivas JJ, Gómez PA, Cabrera A (1999) Risk factors predicting recurrence in patients operated on for intracranial meningioma. A Multivariate Analysis Acta Neurochir (Wien) 141:921–932. https://doi.org/10.1007/s007010050398CrossRefPubMed

Bayley JC, Hadley CC, Harmanci AO, Harmanci AS, Klisch TJ, Patel AJ (2022) Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. Sci Adv 8:1. https://doi.org/10.1126/sciadv.abm6247CrossRef

Behling F, Fodi C, Gepfner-Tuma I, Kaltenbach K, Renovanz M, Paulsen F, Skardelly M, Honegger J, Tatagiba M, Schittenhelm J, Tabatabai G (2021) H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort. Neuro Oncol 23:1273–1281. https://doi.org/10.1093/neuonc/noaa303CrossRefPubMed

Commins DL, Atkinson RD, Burnett ME (2007) Review of meningioma histopathology. Neurosurg Focus 23:E3. https://doi.org/10.3171/FOC-07/10/E3CrossRefPubMed

Driver J, Hoffman SE, Tavakol S, Woodward E, Maury EA, Bhave V, Greenwald NF, Nassiri F, Aldape K, Zadeh G, Choudhury A, Vasudevan HN, Magill ST, Raleigh DR, Abedalthagafi M, Aizer AA, Alexander BM, Ligon KL, Reardon DA, Wen PY, Al-Mefty O, Ligon AH, Dubuc AM, Beroukhim R, Claus EB, Dunn IF, Santagata S, Linda Bi W (2022) A molecularly integrated grade for meningioma. Neuro Oncol 24:796–808. https://doi.org/10.1093/neuonc/noab213CrossRefPubMed

10.

Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634. https://doi.org/10.1136/bmj.315.7109.629CrossRefPubMedPubMedCentral

11.

Gauchotte G, Peyre M, Pouget C, Cazals-Hatem D, Polivka M, Rech F, Varlet P, Loiseau H, Lacomme S, Mokhtari K, Kalamarides M, Bielle F (2020) Prognostic value of histopathological features and loss of H3K27me3 immunolabeling in anaplastic meningioma: a multicenter retrospective study. J Neuropathol Exp Neurol 79:754–762. https://doi.org/10.1093/jnen/nlaa038CrossRefPubMed

12.

Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558. https://doi.org/10.1002/sim.1186CrossRefPubMed

13.

Hua L, Ren L, Wu Q, Deng J, Chen J, Cheng H, Wang D, Chen H, Xie Q, Wakimoto H, Gong Y (2023) Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk. J Neurooncol 161:267–275. https://doi.org/10.1007/s11060-022-04169-3CrossRefPubMed

14.

Hua L, Wang D, Zhu H, Deng J, Luan S, Chen H, Sun S, Tang H, Xie Q, Wakimoto H, Gong Y (2020) Long-term outcomes of multimodality management for parasagittal meningiomas. J Neurooncol 147:441–450. https://doi.org/10.1007/s11060-020-03440-9CrossRefPubMed

15.

Jung M, Kim S-I, Lim KY, Bae J, Park C-K, Choi SH, Park S-H, Won J-K (2021) The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma. Hum Pathol 115:96–103. https://doi.org/10.1016/j.humpath.2021.06.005CrossRefPubMed

16.

Kane AJ, Sughrue ME, Rutkowski MJ, Shangari G, Fang S, McDermott MW, Berger MS, Parsa AT (2011) Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer 117:1272–1278. https://doi.org/10.1002/cncr.25591CrossRefPubMed

17.

Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching H-G, Baumgarten P, Herold-Mende C, Wick W, Harter PN, Weller M, von Deimling A, Snuderl M, Sen C, Sahm F (2018) Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol 135:955–963. https://doi.org/10.1007/s00401-018-1844-9CrossRefPubMed

18.

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106CrossRefPubMedPubMedCentral

19.

Ma L-L, Wang Y-Y, Yang Z-H, Huang D, Weng H, Zeng X-T (2020) Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: What are they and which is better? Mil Med Res 7:7. https://doi.org/10.1186/s40779-020-00238-8CrossRefPubMedPubMedCentral

20.

Maier AD, Brøchner CB, Mirian C, Haslund-Vinding J, Bartek J, Ekström TJ, Poulsen FR, Scheie D, Mathiesen T (2022) Loss of H3K27me3 in WHO grade 3 meningioma. Brain Tumor Pathol 39:200–209. https://doi.org/10.1007/s10014-022-00436-3CrossRefPubMed

21.

Mawrin C, Perry A (2010) Pathological classification and molecular genetics of meningiomas. J Neurooncol 99:379–391. https://doi.org/10.1007/s11060-010-0342-2CrossRefPubMed

22.

Mirlacher M, Kasper M, Storz M, Knecht Y, Dürmüller U, Simon R, Mihatsch MJ, Sauter G (2004) Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol 17:1414–1420. https://doi.org/10.1038/modpathol.3800208CrossRefPubMed

23.

Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R, Macklin AM, Khan S, Singh O, Karimi S, Corona RI, Liu LY, Chen CY, Chakravarthy A, Wei Q, Mehani B, Suppiah S, Gao A, Workewych AM, Tabatabai G, Boutros PC, Bader GD, de Carvalho DD, Kislinger T, Aldape K, Zadeh G (2021) A clinically applicable integrative molecular classification of meningiomas. Nature 597:119–125. https://doi.org/10.1038/s41586-021-03850-3CrossRefPubMed

24.

Nassiri F, Wang JZ, Singh O, Karimi S, Dalcourt T, Ijad N, Pirouzmand N, Ng H-K, Saladino A, Pollo B, Dimeco F, Yip S, Gao A, Aldape KD, Zadeh G, Aldape K, Au K, Barnholtz-Sloan J, Behling F, Bi W, Brastianos P, Butowski N, Brodie C, Cohen-Gadol A, Couce M, Dimeco F, Drummond K, Dunn I, Cohen-Gadol A, Galanis E, Galldiks N, Giannini C, Goldbrunner R, Hanemann O, Herold-Mende C, Horbinski C, Huang R, Javadpour M, Jenkinson M, Jungk C, Kaufmann T, Krischek B, Kurz S, Lachance D, Lafougere C, Lamszus K, Lee I, Malta T, Makarenko S, Mawrin C, McDermott M, Millward C, Moliterno-Gunel J, Morokoff A, Nassiri F, Ng HK, Noushmehr H, Perry A, Poisson L, Pollo B, Ragunathan A, Raleigh D, Renovanz M, Ricklefs F, Sahm F, Saladino A, Santacroce A, Santarius T, Schichor C, Schimdt N, Schittenhelm J, Selman W, Shih H, Snyder J, Snuderl M, Sloan A, Suppiah S, Sulman E, Tabatabai G, Tatagiba M, Timmer M, Tonn J-C, von Deimling A, Vogelbaum M, Walbert T, Wang J, Wen P, Westphal M, Yip S, Zadeh G (2021) Loss of H3K27me3 in meningiomas. Neuro Oncol 23:1282–1291. https://doi.org/10.1093/neuonc/noab036CrossRefPubMedPubMedCentral

25.

Och W, Szmuda T, Sikorska B, Springer J, Jaskólski D, Zakrzewska M, Liberski PP (2016) Recurrence-associated chromosomal anomalies in meningiomas: Single-institution study and a systematic review with meta-analysis. Neurol Neurochir Pol 50:439–448. https://doi.org/10.1016/j.pjnns.2016.08.003CrossRefPubMed

26.

Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2021) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol 23:iii1–iii105. https://doi.org/10.1093/neuonc/noab200

27.

Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C, Yip S, Hukin J, Sun Y, Schipper MJ, Chavez L, Margol A, Pekmezci M, Chung C, Banda A, Bayliss JM, Curry SJ, Santi M, Rodriguez FJ, Snuderl M, Karajannis MA, Saratsis AM, Horbinski CM, Carret A-S, Wilson B, Johnston D, Lafay-Cousin L, Zelcer S, Eisenstat D, Silva M, Scheinemann K, Jabado N, McNeely PD, Kool M, Pfister SM, Taylor MD, Hawkins C, Korshunov A, Judkins AR, Venneti S (2017) Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 134:705–714. https://doi.org/10.1007/s00401-017-1752-4CrossRefPubMedPubMedCentral

28.

Pettersson-Segerlind J, Orrego A, Lönn S, Mathiesen T (2011) Long-term 25-year follow-up of surgically treated parasagittal meningiomas. World Neurosurg 76:564–571. https://doi.org/10.1016/j.wneu.2011.05.015CrossRefPubMed

29.

Prieto-Granada CN, Wiesner T, Messina JL, Jungbluth AA, Chi P, Antonescu CR (2016) Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol 40:479–489. https://doi.org/10.1097/PAS.0000000000000564CrossRefPubMedPubMedCentral

30.

Riemenschneider MJ, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 5:1045–1054. https://doi.org/10.1016/S1474-4422(06)70625-1CrossRefPubMed

31.

Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching H-G, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18:682–694. https://doi.org/10.1016/S1470-2045(17)30155-9CrossRefPubMed

32.

Samal S, Patnaik A, Purkait S, Sahu F (2020) Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas – prognostic biomarkers for routine practice. Folia Neuropathol 58:133–142. https://doi.org/10.5114/fn.2020.96970CrossRefPubMed

33.

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ Br Med J 349:7647. https://doi.org/10.1136/bmj.g7647CrossRef

34.

Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJJ, Perry A (2016) Diffuse midline gliomas with histone H3–K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol 26:569–580. https://doi.org/10.1111/bpa.12336CrossRefPubMed

35.

Stessin AM, Schwartz A, Judanin G, Pannullo SC, Boockvar JA, Schwartz TH, Stieg PE, Wernicke AG (2012) Does adjuvant external-beam radiotherapy improve outcomes for nonbenign meningiomas? A surveillance, epidemiology, and end results (SEER)–based analysis. J Neurosurg 117:669–675. https://doi.org/10.3171/2012.7.JNS111439CrossRefPubMed

36.

Sun T, Plutynski A, Ward S, Rubin JB (2015) An integrative view on sex differences in brain tumors. Cell Mol Life Sci 72:3323–3342. https://doi.org/10.1007/s00018-015-1930-2CrossRefPubMedPubMedCentral

37.

Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM, Martinez D, Perry A, Lewis PW, Thompson CB, Judkins AR (2014) A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol 128:743–753. https://doi.org/10.1007/s00401-014-1338-3CrossRefPubMedPubMedCentral

38.

Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD (2010) Medical therapies for meningiomas. J Neurooncol 99:365–378. https://doi.org/10.1007/s11060-010-0349-8CrossRefPubMed

Title: Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis
Authors: Gregory Cello
Ruchit V. Patel
James Tanner McMahon
Sandro Santagata
Wenya Linda Bi
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Meningioma
Meningioma
Epigenetics
Published in: Acta Neuropathologica Communications / Issue 1/2023
Electronic ISSN: 2051-5960
DOI: https://doi.org/10.1186/s40478-023-01615-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration

The specific DNA methylation landscape in focal cortical dysplasia ILAE type 3D

CNS neuroblastoma, FOXR2-activated and its mimics: a relevant panel approach for work-up and accurate diagnosis of this rare neoplasm

Inflammasome activation in peritumoral astrocytes is a key player in breast cancer brain metastasis development

Molecular signatures of inherited and acquired sporadic late onset nemaline myopathies

Human tauopathy strains defined by phosphorylation in R1-R2 repeat domains of tau